Europe should adopt WHO recommendations for particulate m...( Europe must adopt the World Health O...),Health
Europe must adopt the World Health Organization (WHO) standard on fine particulate matter pollution if it is to significantly curb needless premature deaths, concludes research in the Journal of Epidemiology and Community Health.
Europe wants to cap average levels of fine particulate matter pollution (PM2.5) at 20 g/m 3 by 2010.
But the equivalent standard recommended by the US Environmental Protection Agency is 15 g/m 3, while that recommended by the World Health Organization is 10 g/m 3 .
Fine particulate matter has been associated with an increase in death from all causes, and particularly respiratory and cardiovascular diseases.
Using validated data on health outcomes and exposure to pollution for 26 European cities, covering more than 40 million inhabitants, the researchers calculated the expected number of deaths that could be delayed for all three standards.
Estimated average annual levels of fine particulate matter ranged from 17 to 61 g/m3. London and Dublin were the cleanest of the 26 cities, with levels below 10 /m 3.
Athens in Greece, Cracow in Poland, and the Italian capital Rome were among the worst offenders, with levels above 25 g/m 3.
The calculations showed that reducing average levels to15 g/m 3 could delay at least 1.6% of premature deaths among those aged 30 and above, a rate four times greater than could be achieved by levels of 25 g/m 3 and two times greater than could be achieved at 20 g/m 3.
But cutting levels to 10 g/m 3, as recommended by the WHO, could produce a fall in early deaths that would be seven times greater, the calculations suggest.
Every city, but London and Dublin would benefit, say the authors, with reductions in premature deaths ranging from 0.8% to 9%, and 80% of thisl could be achieved within five years.
The authors point out that it is not just lives that would be saved.
The US Environmental Prote
'/>"/>
| Contact: Emma Dickinson edickinson@bmj.com 44-020-738-36529 BMJ-British Medical Journal Source:Eurekalert |
Related medicine news :
1. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
2. Columbus Carried Syphilis From New World to Europe, Study Suggests
3. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
4. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
5. Phylonix granted broad European patent for transplanting human cells into zebrafish
6. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
7. Far flung food: Europes distant diets
8. Submission of Marketing Authorisation Application for Dapoxetine in Europe
9. LifeScience Alley 2007: German Healthcare Market Offers Gateway to Europe
10. Innocoll Receives Intends to Grant Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
11. Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |